NVCR News and Press, NovoCure Limited From 04/30/20

Quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019 Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities ...

EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune fo...

Glioblastoma is the most invasive and malignant type of brain cancer. If untreated, patients survive for a medial duration of merely three to four months from the initial development of tumors. The condition affects more than 27,000 adults in North America annually. Since 2015, Novocure (NAS...

Inspire Medical Systems (NYSE: INSP ) initiated with Overweight rating and $74 (19% upside) price target at Piper Sandler. More news on: Inspire Medical Systems, Inc., Prevail Therapeutics Inc., Stereotaxis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BioNano Genomics (NASDAQ: BNGO ) initiated with Outperform rating and $1.50 (443% upside) price target at Oppenheimer. Shares up  19%  premarket. More news on: Bionano Genomics, Inc., NovoCure Limited, Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ,...

Novocure to report first quarter financial results on Thursday, April 30, 2020 Novocure (NASDAQ: NVCR) today provided an update on its response to the global COVID-19 pandemic and an initial evaluation of the impact the pandemic may have on Novocure’s general business operations...

Directive mandates reimbursement coverage of Tumor Treating Fields for patients with newly diagnosed glioblastoma by the compulsory health insurance system Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, or G-BA, has updated its directive for Contracted...

Shares of  Novocure (NASDAQ: NVCR) ,  Insulet (NASDAQ: PODD) , and  Dexcom   (NASDAQ: DXCM)  all rose by double digits in afternoon trading on Thursday. As of 3:15 p.m. EDT, these healthcare stocks  were up 10%, 7%, and 10%, respectively.  The major U.S. ...

Shares of  ShockWave Medical   (NASDAQ: SWAV) , Novocure (NASDAQ: NVCR) , and Guardant Health (NASDAQ: GH) all plunged on Monday. These healthcare stocks  ended the trading session down 15%, 12%, and 17%, respectively.  The Federal Open Market Committee, which i...

Data from study on Tumor Treating Fields in combination with anti-PD-1 therapy published in Cancer Immunology, Immunotherapy Novocure (NASDAQ: NVCR) announced today that preclinical data on Tumor Treating Fields in combination with anti-PD-1 therapy were published in the peer-reviewe...